The trend with drug benefit companies is to insure at the cost of the generic. What constituents often say is that when they go to have their prescription filled, the generic is not there and they have to buy the brand name pharmaceutical.
My question is whether these brand name pharmaceuticals are taking greater ownership in the generics, then holding back production of the generics so that the brand name pharmaceuticals will have to be bought by the patients.